ARTICLE | Deals
BMS gains license to BridgeBio’s SHP-2, already in deal for Opdivo combo
Pharma pays $90M up front for rights to small molecule that could become a once-daily option in combinations for some cancers
May 12, 2022 8:24 PM UTC
BMS is paying BridgeBio $90 million up front to gain an exclusive license to the biotech’s clinical SHP-2 inhibitor, which the partners believe could be a best-in-class therapy for certain cancers in combinations with once-daily dosing.
The deal gives Bristol Myers Squibb Co. (NYSE:BMY) rights to BBP-398, a program that was already in a clinical development partnership with BridgeBio Pharma Inc. (NASDAQ:BBIO) under which it is being tested in combination with Opdivo nivolumab, the pharma’s PD-1 inhibitor...